Is Arcadia Biosciences Stock a Good Investment?
Arcadia Biosciences Investment Advice | RKDA |
- Examine Arcadia Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Arcadia Biosciences' leadership team and their track record. Good management can help Arcadia Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Agricultural Products & Services space and any emerging trends that could impact Arcadia Biosciences' business and its evolving consumer preferences.
- Compare Arcadia Biosciences' performance and market position to its competitors. Analyze how Arcadia Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Arcadia Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Arcadia Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Arcadia Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Arcadia Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Arcadia Biosciences Stock
Researching Arcadia Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.84. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Arcadia Biosciences recorded a loss per share of 6.77. The entity last dividend was issued on the 24th of January 2018. The firm had 1:40 split on the 1st of March 2023.
To determine if Arcadia Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arcadia Biosciences' research are outlined below:
| Arcadia Biosciences is way too risky over 90 days horizon | |
| Arcadia Biosciences appears to be risky and price may revert if volatility continues | |
| Arcadia Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 5.33 M. Net Loss for the year was (13.99 M) with loss before overhead, payroll, taxes, and interest of (2.22 M). | |
| Arcadia Biosciences currently holds about 21.23 M in cash with (15.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96. | |
| Arcadia Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates PFIE, CDMO, RKDA on Behalf of Shareholders |
Arcadia Biosciences Quarterly Liabilities And Stockholders Equity |
|
Arcadia Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arcadia Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arcadia Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Arcadia Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Arcadia Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-22 | 2024-03-31 | -2.21 | -1.78 | 0.43 | 19 | ||
2018-03-20 | 2017-12-31 | -2 | -1.39 | 0.61 | 30 | ||
2024-08-13 | 2024-06-30 | 1.55 | 0.78 | -0.77 | 49 | ||
2021-08-16 | 2021-06-30 | -10.93 | -9.6 | 1.33 | 12 | ||
2023-11-09 | 2023-09-30 | -3.19 | -1.44 | 1.75 | 54 | ||
2023-08-10 | 2023-06-30 | -4.8 | -2.65 | 2.15 | 44 | ||
2020-11-12 | 2020-09-30 | -21.73 | -24.0 | -2.27 | 10 | ||
2020-03-25 | 2019-12-31 | -23 | -20.0 | 3.0 | 13 |
Know Arcadia Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arcadia Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcadia Biosciences backward and forwards among themselves. Arcadia Biosciences' institutional investor refers to the entity that pools money to purchase Arcadia Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Oliver Lagore Vanvalin Investment Group | 2024-09-30 | 4.0 | Royal Bank Of Canada | 2024-06-30 | 2.0 | Harbour Investments, Inc. | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 0.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Mariner Wealth Advisors Llc | 2024-09-30 | 25 K | Vanguard Group Inc | 2024-09-30 | 14 K | State Street Corp | 2024-09-30 | 12.1 K | Tower Research Capital Llc | 2024-09-30 | 1.8 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 607 |
Arcadia Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.6 M.Market Cap |
|
Arcadia Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.86) | (0.91) | |
| Return On Assets | (0.71) | (0.74) | |
| Return On Equity | (1.09) | (1.03) |
Determining Arcadia Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Arcadia Biosciences is a good buy. For example, gross profit margin measures Arcadia Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Arcadia Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Arcadia Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arcadia Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Arcadia Biosciences' management manipulating its earnings.
Evaluate Arcadia Biosciences' management efficiency
Arcadia Biosciences has return on total asset (ROA) of (0.3872) % which means that it has lost $0.3872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5265) %, meaning that it created substantial loss on money invested by shareholders. Arcadia Biosciences' management efficiency ratios could be used to measure how well Arcadia Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 14, 2024, Return On Tangible Assets is expected to decline to -0.75. In addition to that, Return On Capital Employed is expected to decline to -0.91. At present, Arcadia Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 5.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.27 | 9.76 | |
| Tangible Book Value Per Share | 10.24 | 9.73 | |
| Enterprise Value Over EBITDA | 0.12 | 0.12 | |
| Price Book Value Ratio | 0.30 | 0.32 | |
| Enterprise Value Multiple | 0.12 | 0.12 | |
| Price Fair Value | 0.30 | 0.32 | |
| Enterprise Value | -1.6 M | -1.6 M |
Management at Arcadia Biosciences focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 1.275 |
Basic technical analysis of Arcadia Stock
As of the 14th of December 2024, Arcadia Biosciences shows the risk adjusted performance of 0.1067, and Mean Deviation of 6.05. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Arcadia Biosciences, as well as the relationship between them.Arcadia Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcadia Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcadia Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcadia Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arcadia Biosciences' Outstanding Corporate Bonds
Arcadia Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arcadia Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arcadia bonds can be classified according to their maturity, which is the date when Arcadia Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Arcadia Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Arcadia Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1067 | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 6.05 | |||
| Semi Deviation | 5.24 | |||
| Downside Deviation | 6.96 | |||
| Coefficient Of Variation | 746.14 | |||
| Standard Deviation | 14.12 | |||
| Variance | 199.24 | |||
| Information Ratio | 0.1269 | |||
| Jensen Alpha | 2.11 | |||
| Total Risk Alpha | 0.1276 | |||
| Sortino Ratio | 0.2573 | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 106.7 | |||
| Value At Risk | (8.55) | |||
| Potential Upside | 11.39 | |||
| Downside Variance | 48.51 | |||
| Semi Variance | 27.42 | |||
| Expected Short fall | (7.97) | |||
| Skewness | 5.55 | |||
| Kurtosis | 39.71 |
| Risk Adjusted Performance | 0.1067 | |||
| Market Risk Adjusted Performance | (0.72) | |||
| Mean Deviation | 6.05 | |||
| Semi Deviation | 5.24 | |||
| Downside Deviation | 6.96 | |||
| Coefficient Of Variation | 746.14 | |||
| Standard Deviation | 14.12 | |||
| Variance | 199.24 | |||
| Information Ratio | 0.1269 | |||
| Jensen Alpha | 2.11 | |||
| Total Risk Alpha | 0.1276 | |||
| Sortino Ratio | 0.2573 | |||
| Treynor Ratio | (0.73) | |||
| Maximum Drawdown | 106.7 | |||
| Value At Risk | (8.55) | |||
| Potential Upside | 11.39 | |||
| Downside Variance | 48.51 | |||
| Semi Variance | 27.42 | |||
| Expected Short fall | (7.97) | |||
| Skewness | 5.55 | |||
| Kurtosis | 39.71 |
Consider Arcadia Biosciences' intraday indicators
Arcadia Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arcadia Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Arcadia Biosciences Corporate Filings
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 22nd of November 2024 Other Reports | ViewVerify | |
8K | 23rd of August 2024 An amendment to a previously filed Form 8-K | ViewVerify |
F4 | 21st of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Arcadia Stock media impact
Far too much social signal, news, headlines, and media speculation about Arcadia Biosciences that are available to investors today. That information is available publicly through Arcadia media outlets and privately through word of mouth or via Arcadia internal channels. However, regardless of the origin, that massive amount of Arcadia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arcadia Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arcadia Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arcadia Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arcadia Biosciences alpha.
Arcadia Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Arcadia Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Arcadia Biosciences Corporate Management
| Belinda Yao | VP Operations | Profile | |
| Brian Schaffer | Senior Sales | Profile | |
| Kevin Hodges | VP Operations | Profile | |
| Mark Kawakami | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Earnings Share (6.77) | Revenue Per Share 3.802 | Quarterly Revenue Growth (0.04) | Return On Assets (0.39) |
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Arcadia Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.